Black Opal Ventures Releases Annual Impact Report, Spotlighting Frontier Technology Companies Solving Healthcare's Complex Challenges
NEW YORK--(BUSINESS WIRE)--Black Opal Ventures, a visionary technology venture capital firm co-founded by Managing Directors Dr. Tara Bishop and Eileen Tanghal, has released its annual Impact Report (link) for 2024. The report showcases the firm's investment philosophy and celebrates the transformative impact of its portfolio companies, which are leveraging frontier technologies to tackle the world's most pressing and complex challenges in healthcare today.
Frontier technologies like generative AI, robotics, bioengineering, and advanced computing are transforming how diseases are diagnosed, treated, and prevented—delivering real impact for patients and providers alike
Share
'U.S. healthcare spending is expected to exceed $6 trillion by 2028,' said Dr. Tara Bishop, Black Opal Ventures co-founder and Managing Director. 'Despite this, there are a multitude of unsolved problems, and a dire need for capital to make vital advancements. Our commitment stands behind technologies and companies that address issues while challenging old systems and scaling access. Our investments thrive at the intersection of healthcare and technology, driving innovation to reshape the future of healthcare. By empowering pioneering start-ups, we are fostering advancements that make a meaningful difference in communities across the U.S and globally.'
From fertility labs and surgical centers to oncology pipelines and remote monitoring, Black Opal Ventures' portfolio companies are ushering in a new era of healthcare and life sciences by revolutionizing diagnostics, treatment, and patient care through frontier technologies that are scalable, precise, personalized, and inclusive. They include Ansa Biotechnologies, Blaze.Tech, Conceivable Life Sciences, Empatica, FlyteHealth, Hyro, Oath, Optellum, Outpace, Parasail, and TigerGraph, all of which are utilizing and advancing frontier technology including:
Applications in drug discovery and clinical decision support as well as patient communication now use Generative AI through language models and intelligent automation to function effectively.
Robotics improves precision and efficiency while scaling up care delivery especially in surgical environments and laboratory automation.
Bioengineering drives progress in gene synthesis alongside protein design and next-generation therapies to develop novel treatments for complex diseases.
Real-time connections between patients, healthcare providers, and data streams are possible because of advanced Communication Technologies.
Advanced Computing, which includes the combination of high-performance processors and distributed GPU networks, enables the development and expansion of powerful AI models for diagnostic applications as well as population health management.
'Frontier technologies are emerging at the intersection of radical scientific breakthroughs and real-world implementation. Our investments are at the collision of healthcare and technology in order to redefine healthcare,' said Eileen Tanghal, co-founder and Managing Director of Black Opal Ventures. 'Generative AI, robotics, bioengineering, and advanced computing are transforming how diseases are diagnosed, treated, and prevented—delivering real impact for patients and providers alike.'
Black Opal Ventures strategically aligns its investment approach with several United Nations Sustainable Development Goals (SDGs), particularly SDGs 3 (Good Health and Well-being), 5 (Gender Equality), 9 (Industry, Innovation, and Infrastructure), 10 (Reduced Inequalities), and 16 (Peace, Justice, and Strong Institutions). Black Opal Ventures is driving inclusivity across the venture capital and start-up ecosystems to ensure that technology-driven healthcare solutions reach the communities that need them most.
About Black Opal Ventures:
Black Opal Ventures is a visionary venture capital firm investing in frontier technologies to address the world's most complex challenges. The firm was founded in 2021 by General Partners Dr. Tara Bishop and Eileen Tanghal. The inaugural fund aims to improve health outcomes by investing in companies at the intersection of science and technology. Learn more at https://www.blackopalventures.com/.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 hours ago
- Yahoo
Cameco Reports Expected Increase in Its Share of Westinghouse 2025 Adjusted EBITDA
All amounts in Canadian dollars unless specified otherwise SASKATOON, Saskatchewan, June 06, 2025--(BUSINESS WIRE)--Cameco (TSX: CCO; NYSE: CCJ) reports an expected increase of approximately $170 million (US) in our 49% equity share of Westinghouse Electric Company's (Westinghouse) 2025 second quarter and annual adjusted EBITDA. The expected increase is tied to Westinghouse's participation in the construction project for two nuclear reactors at the Dukovany power plant in the Czech Republic. This expected increase will be taken into consideration in determining the 2025 distribution payable by Westinghouse to Cameco. In addition to the increase in adjusted EBITDA in 2025, we expect significant financial benefits for Westinghouse, as a subcontractor, over the term of the Dukovany construction project and related to the provision of the fuel fabrication services required for both reactors for a specified period. The outlook for Westinghouse's compound annual growth rate for adjusted EBITDA remains 6% to 10% over the next five years, excluding the impact of the expected $170 million (US) increase in its 2025 adjusted EBITDA. Cameco owns a 49% interest in Westinghouse and its partner, Brookfield Renewable Partners, owns the remaining 51%. Caution about forward-looking informationThis news release includes statements and information about our expectations for the future, which we refer to as forward-looking information. Forward-looking information is based on our current views, which can change significantly, and actual results and events may be significantly different from what we currently expect. Examples of forward-looking information in this news release include our expectations regarding: Westinghouse's participation in the Dukovany power plant construction project; an increase in Westinghouse's adjusted EBITDA; Westinghouse taking this increase into consideration in determining the 2025 distribution payable to Cameco; the financial benefits for Westinghouse, as subcontractor, over the term of the Dukovany construction project and the expected future growth in Westinghouse's compound annual growth rate for adjusted EBITDA. Material risks that could lead to different results include the risk that Westinghouse is not able to participate in the Dukovany construction project on a basis that achieves the currently expected benefits to Westinghouse for any reason, or that Cameco may not derive the expected increases in its share of Westinghouse's adjusted EBITDA, or that Westinghouse does not achieve the expected future annual growth in adjusted EBITDA. In presenting the forward-looking information, we have made material assumptions which may prove incorrect about Westinghouse's participation in the Dukovany construction project and related potential benefits to Westinghouse, and continuing growth in Westinghouse's compound annual growth rate for adjusted EBITDA. Non-IFRS MeasuresAdjusted EBITDA is a measure that does not have a standardized meaning or a consistent basis of calculation under International Financial Reporting Standards (a non-IFRS measure). Westinghouse's adjusted EBITDA is defined as its net income, adjusted for the impact of certain expenses, costs, charges or benefits incurred in such period which are either not indicative of underlying business performance or that impact the ability to assess the operating performance of its business. For more information regarding our use of this non-IFRS measure see our most recent annual and quarterly Management's Discussion and Analysis. ProfileCameco is one of the largest global providers of the uranium fuel needed to power a secure energy future. Our competitive position is based on our controlling ownership of the world's largest high-grade reserves and low-cost operations, as well as significant investments across the nuclear fuel cycle, including ownership interests in Westinghouse Electric Company and Global Laser Enrichment. Utilities around the world rely on Cameco to provide global nuclear fuel solutions for the generation of safe, reliable, carbon-free nuclear power. Our shares trade on the Toronto and New York stock exchanges. Our head office is in Saskatoon, Saskatchewan, Canada. As used in this news release, the terms we, us, our, the Company and Cameco mean Cameco Corporation and its subsidiaries unless otherwise indicated. View source version on Contacts Investor inquiries Cory Kos 306-716-6782 cory_kos@ Media inquiries Veronica Baker 306-385-5541 veronica_baker@ Sign in to access your portfolio
Yahoo
15 hours ago
- Yahoo
Cameco Reports Expected Increase in Its Share of Westinghouse 2025 Adjusted EBITDA
All amounts in Canadian dollars unless specified otherwise SASKATOON, Saskatchewan, June 06, 2025--(BUSINESS WIRE)--Cameco (TSX: CCO; NYSE: CCJ) reports an expected increase of approximately $170 million (US) in our 49% equity share of Westinghouse Electric Company's (Westinghouse) 2025 second quarter and annual adjusted EBITDA. The expected increase is tied to Westinghouse's participation in the construction project for two nuclear reactors at the Dukovany power plant in the Czech Republic. This expected increase will be taken into consideration in determining the 2025 distribution payable by Westinghouse to Cameco. In addition to the increase in adjusted EBITDA in 2025, we expect significant financial benefits for Westinghouse, as a subcontractor, over the term of the Dukovany construction project and related to the provision of the fuel fabrication services required for both reactors for a specified period. The outlook for Westinghouse's compound annual growth rate for adjusted EBITDA remains 6% to 10% over the next five years, excluding the impact of the expected $170 million (US) increase in its 2025 adjusted EBITDA. Cameco owns a 49% interest in Westinghouse and its partner, Brookfield Renewable Partners, owns the remaining 51%. Caution about forward-looking informationThis news release includes statements and information about our expectations for the future, which we refer to as forward-looking information. Forward-looking information is based on our current views, which can change significantly, and actual results and events may be significantly different from what we currently expect. Examples of forward-looking information in this news release include our expectations regarding: Westinghouse's participation in the Dukovany power plant construction project; an increase in Westinghouse's adjusted EBITDA; Westinghouse taking this increase into consideration in determining the 2025 distribution payable to Cameco; the financial benefits for Westinghouse, as subcontractor, over the term of the Dukovany construction project and the expected future growth in Westinghouse's compound annual growth rate for adjusted EBITDA. Material risks that could lead to different results include the risk that Westinghouse is not able to participate in the Dukovany construction project on a basis that achieves the currently expected benefits to Westinghouse for any reason, or that Cameco may not derive the expected increases in its share of Westinghouse's adjusted EBITDA, or that Westinghouse does not achieve the expected future annual growth in adjusted EBITDA. In presenting the forward-looking information, we have made material assumptions which may prove incorrect about Westinghouse's participation in the Dukovany construction project and related potential benefits to Westinghouse, and continuing growth in Westinghouse's compound annual growth rate for adjusted EBITDA. Non-IFRS MeasuresAdjusted EBITDA is a measure that does not have a standardized meaning or a consistent basis of calculation under International Financial Reporting Standards (a non-IFRS measure). Westinghouse's adjusted EBITDA is defined as its net income, adjusted for the impact of certain expenses, costs, charges or benefits incurred in such period which are either not indicative of underlying business performance or that impact the ability to assess the operating performance of its business. For more information regarding our use of this non-IFRS measure see our most recent annual and quarterly Management's Discussion and Analysis. ProfileCameco is one of the largest global providers of the uranium fuel needed to power a secure energy future. Our competitive position is based on our controlling ownership of the world's largest high-grade reserves and low-cost operations, as well as significant investments across the nuclear fuel cycle, including ownership interests in Westinghouse Electric Company and Global Laser Enrichment. Utilities around the world rely on Cameco to provide global nuclear fuel solutions for the generation of safe, reliable, carbon-free nuclear power. Our shares trade on the Toronto and New York stock exchanges. Our head office is in Saskatoon, Saskatchewan, Canada. As used in this news release, the terms we, us, our, the Company and Cameco mean Cameco Corporation and its subsidiaries unless otherwise indicated. View source version on Contacts Investor inquiries Cory Kos 306-716-6782 cory_kos@ Media inquiries Veronica Baker 306-385-5541 veronica_baker@
Business Wire
15 hours ago
- Business Wire
Cameco Reports Expected Increase in Its Share of Westinghouse 2025 Adjusted EBITDA
SASKATOON, Saskatchewan--(BUSINESS WIRE)-- Cameco (TSX: CCO; NYSE: CCJ) reports an expected increase of approximately $170 million (US) in our 49% equity share of Westinghouse Electric Company's (Westinghouse) 2025 second quarter and annual adjusted EBITDA. The expected increase is tied to Westinghouse's participation in the construction project for two nuclear reactors at the Dukovany power plant in the Czech Republic. This expected increase will be taken into consideration in determining the 2025 distribution payable by Westinghouse to Cameco. In addition to the increase in adjusted EBITDA in 2025, we expect significant financial benefits for Westinghouse, as a subcontractor, over the term of the Dukovany construction project and related to the provision of the fuel fabrication services required for both reactors for a specified period. The outlook for Westinghouse's compound annual growth rate for adjusted EBITDA remains 6% to 10% over the next five years, excluding the impact of the expected $170 million (US) increase in its 2025 adjusted EBITDA. Cameco owns a 49% interest in Westinghouse and its partner, Brookfield Renewable Partners, owns the remaining 51%. Caution about forward-looking information This news release includes statements and information about our expectations for the future, which we refer to as forward-looking information. Forward-looking information is based on our current views, which can change significantly, and actual results and events may be significantly different from what we currently expect. Examples of forward-looking information in this news release include our expectations regarding: Westinghouse's participation in the Dukovany power plant construction project; an increase in Westinghouse's adjusted EBITDA; Westinghouse taking this increase into consideration in determining the 2025 distribution payable to Cameco; the financial benefits for Westinghouse, as subcontractor, over the term of the Dukovany construction project and the expected future growth in Westinghouse's compound annual growth rate for adjusted EBITDA. Material risks that could lead to different results include the risk that Westinghouse is not able to participate in the Dukovany construction project on a basis that achieves the currently expected benefits to Westinghouse for any reason, or that Cameco may not derive the expected increases in its share of Westinghouse's adjusted EBITDA, or that Westinghouse does not achieve the expected future annual growth in adjusted EBITDA. In presenting the forward-looking information, we have made material assumptions which may prove incorrect about Westinghouse's participation in the Dukovany construction project and related potential benefits to Westinghouse, and continuing growth in Westinghouse's compound annual growth rate for adjusted EBITDA. Non-IFRS Measures Adjusted EBITDA is a measure that does not have a standardized meaning or a consistent basis of calculation under International Financial Reporting Standards (a non-IFRS measure). Westinghouse's adjusted EBITDA is defined as its net income, adjusted for the impact of certain expenses, costs, charges or benefits incurred in such period which are either not indicative of underlying business performance or that impact the ability to assess the operating performance of its business. For more information regarding our use of this non-IFRS measure see our most recent annual and quarterly Management's Discussion and Analysis. Profile Cameco is one of the largest global providers of the uranium fuel needed to power a secure energy future. Our competitive position is based on our controlling ownership of the world's largest high-grade reserves and low-cost operations, as well as significant investments across the nuclear fuel cycle, including ownership interests in Westinghouse Electric Company and Global Laser Enrichment. Utilities around the world rely on Cameco to provide global nuclear fuel solutions for the generation of safe, reliable, carbon-free nuclear power. Our shares trade on the Toronto and New York stock exchanges. Our head office is in Saskatoon, Saskatchewan, Canada. As used in this news release, the terms we, us, our, the Company and Cameco mean Cameco Corporation and its subsidiaries unless otherwise indicated.
